Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00326118
Other study ID # 106445
Secondary ID 1064461064491064
Status Completed
Phase Phase 3
First received
Last updated
Start date June 1, 2006
Est. completion date November 6, 2007

Study information

Verified date September 2016
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.

In the extension phase, at Years 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Description:

This multicenter study is open and has 2 treatment groups with Hiberix™ + a commercially available MenC vaccine as active controls. Priorix™ is given concomitantly in both groups. In the primary phase, two blood samples are taken from all subjects for immunogenicity analyses: before and one month after vaccination. In the extension phase, at Year 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase.


Recruitment information / eligibility

Status Completed
Enrollment 433
Est. completion date November 6, 2007
Est. primary completion date November 1, 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 18 Months
Eligibility Inclusion Criteria:

Primary phase:

- Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.

- A male or female between, and including, 12 and 18 months of age at the time of vaccination.

- Written informed consent obtained from the parent or guardian of the subject.

- Free of obvious health problems as established by medical history and clinical examination before entering into the study.

- Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.

- Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.

Long-term persistence phase:

- Having participated in the vaccination study 106445

Exclusion Criteria:

For the primary vaccination phase:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.

- Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.

- Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.

- Previous administration of a booster dose of Hib vaccine.

- Previous vaccination against measles, mumps, rubella.

- History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.

- Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.

- A family history of congenital or hereditary immunodeficiency.

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

- Major congenital defects or serious chronic illness.

- History of neurological disorders or more than one episode of febrile convulsion.

- Acute disease at the time of enrolment.

- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Additional exclusion criteria for the long-term persistence phase: to be checked each year.

- Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.

- History of H. influenzae type b, meningococcal serogroup C diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
One intramuscular dose at 12-18 months of age
Priorix™
One subcutaneous dose at 12-18 months of age
Hiberix™
One intramuscular dose at 12-18 months of age.
Meningitec™
One intramuscular dose at 12-18 months of age

Locations

Country Name City State
Australia GSK Investigational Site Carlton Victoria
Australia GSK Investigational Site Garran Australian Capital Territory
Australia GSK Investigational Site Herston Queensland
Australia GSK Investigational Site North Adelaide South Australia
Australia GSK Investigational Site Perth Western Australia
Australia GSK Investigational Site Randwick New South Wales
Australia GSK Investigational Site Westmead New South Wales

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Australia, 

References & Publications (5)

Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 3 year follow-up. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.

Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 4 year follow-up. Abstract presented at the Communicable Diseases Network Australia - Communicable Diseases Control Conference 2013, Canberra, Australia, 19-20 March 2013.

Booy R et al. Prolonged immunogenicity and safety of the HibMenC-TT conjugate vaccine in Hib-Primed toddlers. Abstract presented at the PHAA Communicable Disease Conference. Canberra, Australia, 4-6 April 2011.

Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2. — View Citation

Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J. 2013 Feb;32(2):169-74. doi: 10.1097/INF.0b013e3182787bff. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection. 1 month after vaccination
Primary Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection. 1 month after vaccination
Secondary Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values rSBA-MenC titers cut-off values assessed were greater than or equal to (=) 1:8 (indicative of seroprotection) and = 1:128 titers.
Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Secondary Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values rSBA-MenC titers cut-off values assessed were greater than or equal to (=)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. 5 years after vaccination
Secondary Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Secondary Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. 5 years after vaccination
Secondary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection). Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Secondary Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection). 5 years after vaccination
Secondary Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Concentrations are given as Geometric Mean Concentrations (GMCs). Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Secondary Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Concentrations are given as Geometric Mean Concentrations (GMCs). 5 years after vaccination
Secondary Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (=) 0.30 µg/mL and = 2.0 µg/mL. Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Secondary Anti-polysaccharide C (Anti-PSC) Antibody Concentrations Concentrations given as Geometric Mean Concentrations (GMCs). Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Secondary Number of Subjects Reporting Solicited Local and General Symptoms Solicited local symptoms assessed include pain, redness and swelling at the injection site.
Solicited general symptoms assessed include drowsiness, fever (= 38°C), irritability and loss of appetite.
Within 4 days (Day 0 -Day 3) after vaccination
Secondary Number of Subjects Reporting Unsolicited Symptoms Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event. Within 31 days (Day 0 - Day 30) after vaccination
Secondary Number of Subjects Reporting Serious Adverse Events (SAEs) A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject.
For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.
Throughout the entire study period (up to year 5)
See also
  Status Clinical Trial Phase
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00153556 - Study to Eliminate Hib Carriage in Rural Alaska Native Villages Phase 4
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Completed NCT01983540 - Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT00401531 - Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Phase 3
Completed NCT00376779 - Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age Phase 2
Completed NCT00831311 - Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants Phase 2
Completed NCT01457547 - Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Phase 4
Completed NCT00254917 - Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Phase 4
Completed NCT01453998 - Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Phase 2
Completed NCT01449812 - Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Phase 3
Completed NCT00808392 - Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b Phase 3
Completed NCT00307567 - Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 Phase 2
Completed NCT00323050 - Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects Phase 3
Completed NCT00325156 - Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Phase 4